Nintedanib
Also known as: Vargatef · Ofev · Nintedanib Accord · Nintedanib Viatris · Nintedanib Capsules, 100 mg and 150 mg
General information only. Anpheros does not diagnose and does not recommend treatment. Talk to a doctor or pharmacist about your situation. In an emergency, call 112 (or your local emergency number).
In short
In the European Union, nintedanib is indicated in adults for the treatment of idiopathic pulmonary fibrosis, and in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic, or locally recurrent non-small cell lung cancer of adenocarcinoma tumour histology after first-line chemotherapy. In the United States, nintedanib is a kinase inhibitor indicated in adults for the treatment of idiopathic pulmonary fibrosis and for the treatment of chronic fibrosing interstitial lung diseases with a progressive phenotype. Nintedanib is also listed by the cited source as having an approved use for systemic sclerosis.
From: Source: European Medicines Agency (EMA), Ofev — EPAR, 12/10/2026. © European Medicines Agency. · Source: European Medicines Agency (EMA), Vargatef — EPAR, 10/06/2026. © European Medicines Agency. · Data provided by the U.S. Food and Drug Administration. · Source: European Medicines Agency (EMA) — EPAR. © European Medicines Agency.
AI-generated summary of the sources cited on this page, checked automatically against them. Not reviewed by a clinician; not medical advice.
Codes
- RxNorm
- 1592737 nintedanib
- EMA
- EMEA/H/C/002569, EMEA/H/C/003821, EMEA/H/C/006179, EMEA/H/C/006486
Official indications
Quoted unchanged from official product information, in English. Listed alphabetically by product, not ranked.
FDA (USA) Nintedanib
1 INDICATIONS AND USAGE Nintedanib Capsules is a kinase inhibitor indicated in adults for: Treatment of idiopathic pulmonary fibrosis (IPF) ( 1.1 ) Treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype ( 1.2 ) 1.1 Idiopathic Pulmonary Fibrosis Nintedanib Capsules is indicated for the treatment of adults with idiopathic pulmonary fibrosis (IPF). 1.2 Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype Nintedanib Capsules is indicated for the treatment of adults with chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype [see Clinical Studies (14.2) ].
Data provided by the U.S. Food and Drug Administration.
Document date: 20260730 · Official document →
EMA (EU) Ofev
Ofev is indicated in adults for the treatment of Idiopathic Pulmonary Fibrosis (IPF).
Source: European Medicines Agency (EMA), Ofev — EPAR, 12/10/2026. © European Medicines Agency.
Document date: 12/10/2026 · Official document →
EMA (EU) Vargatef
Vargatef is indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first line chemotherapy.
Source: European Medicines Agency (EMA), Vargatef — EPAR, 10/06/2026. © European Medicines Agency.
Document date: 10/06/2026 · Official document →
Related terms in the cited sources
Has an official indication for
- Scleroderma Condition
In alphabetical order.
Other treatments A–Z
What people report
Not enough data yet. Anonymous counts appear here only for groups of at least 20 people who agreed to share them.
External resources
Questions
What is Nintedanib approved for in the European Union?
Ofev is indicated in adults for the treatment of Idiopathic Pulmonary Fibrosis (IPF). (Source: European Medicines Agency (EMA), Ofev — EPAR, 12/10/2026. © European Medicines Agency.)
Sources and attribution
- Source: European Medicines Agency (EMA) — EPAR. © European Medicines Agency.
- Data provided by the U.S. Food and Drug Administration.
- Names other than the official source titles: Anpheros translations and plain-language names, made with AI assistance and checked automatically; the source names are in English.
- This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
- Source: European Medicines Agency (EMA), Ofev — EPAR, 12/10/2026. © European Medicines Agency.
- Source: European Medicines Agency (EMA), Vargatef — EPAR, 10/06/2026. © European Medicines Agency.
Anpheros Search catalog 2026.10.5, published 17 October 2026. About the data →
About this page. This page brings together public information from official sources, each cited where it is used. It is not medical advice, it is not a diagnosis, and it does not tell you which treatment to take.
Treatments. Indications are quoted unchanged from official product information (European Medicines Agency, U.S. Food and Drug Administration). They describe what a medicine is approved for, not whether it is right for you. Approved uses can differ between countries. Always read the package leaflet and follow your doctor's or pharmacist's advice.
What people report. Figures marked "reported by Anpheros users" are anonymous counts from at least 20 people who agreed to share them. They show what people report, not what works, and they are not clinical evidence.
Links between terms. "May be associated with" means the link appears in a cited source. It does not mean you have that condition.
In an emergency, call 112 (or your local emergency number). Do not delay seeking medical help because of something you read here.